Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Influenza A Virus, H3N2 Subtype Infections Overview 10 Therapeutics Development 11 Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Overview 11 Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis 12 Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Development by Companies 13 Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15 Influenza A Virus, H3N2 Subtype Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Influenza A Virus, H3N2 Subtype Infections - Products under Development by Companies 19 Influenza A Virus, H3N2 Subtype Infections - Products under Investigation by Universities/Institutes 21 Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 22 AbbVie Inc 22 AIMM Therapeutics B.V. 23 Aphios Corporation 24 Celltrion, Inc. 25 FluGen, Inc. 26 Glide Pharmaceutical Technologies Limited 27 ILiAD Biotechnologies, LLC 28 Inovio Pharmaceuticals, Inc. 29 Johnson & Johnson 30 Medicago Inc. 31 MedImmune, LLC 32 Mucosis B.V. 33 NanoViricides, Inc. 34 OPKO Health, Inc. 35 Sarepta Therapeutics, Inc. 36 Takeda Pharmaceutical Company Limited 37 VBI Vaccines Inc. 38 Visterra, Inc. 39 Zydus Cadila Healthcare Limited 40 Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Combination Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 APP-0205 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 APP-309 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Aspidasept - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 C-05 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 CR-8020 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 CR-9114 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CTP-27 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Fluad (quadrivalent) - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 FluGEM - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Gamma-Flu - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 influenza [strain A/H3N2] vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 influenza [strain A/H3N2] vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 influenza [strain A/H3N2] vaccine - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 JNJ-872 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 NEO-8877 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 NVINF-1 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 NVINF-2 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 pertussis [strain BPZE1] vaccine - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 PNSIA-28 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 radavirsen - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 REDEE FLU - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Small Molecules for RSV and Influenza A Infections - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 VIS-410 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 97 Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 98 Featured News & Press Releases 98 Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season 98 Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 98 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections - The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects - The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipelineTable of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Influenza A Virus, H3N2 Subtype Infections Overview 10 Therapeutics Development 11 Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Overview 11 Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis 12 Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Development by Companies 13 Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15 Influenza A Virus, H3N2 Subtype Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Influenza A Virus, H3N2 Subtype Infections - Products under Development by Companies 19 Influenza A Virus, H3N2 Subtype Infections - Products under Investigation by Universities/Institutes 21 Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 22 AbbVie Inc 22 AIMM Therapeutics B.V. 23 Aphios Corporation 24 Celltrion, Inc. 25 FluGen, Inc. 26 Glide Pharmaceutical Technologies Limited 27 ILiAD Biotechnologies, LLC 28 Inovio Pharmaceuticals, Inc. 29 Johnson & Johnson 30 Medicago Inc. 31 MedImmune, LLC 32 Mucosis B.V. 33 NanoViricides, Inc. 34 OPKO Health, Inc. 35 Sarepta Therapeutics, Inc. 36 Takeda Pharmaceutical Company Limited 37 VBI Vaccines Inc. 38 Visterra, Inc. 39 Zydus Cadila Healthcare Limited 40 Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Combination Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 APP-0205 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 APP-309 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Aspidasept - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 C-05 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 CR-8020 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 CR-9114 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CTP-27 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Fluad (quadrivalent) - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 FluGEM - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Gamma-Flu - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 influenza [strain A/H3N2] vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 influenza [strain A/H3N2] vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 influenza [strain A/H3N2] vaccine - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 JNJ-872 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 NEO-8877 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 NVINF-1 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 NVINF-2 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 pertussis [strain BPZE1] vaccine - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 PNSIA-28 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 radavirsen - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 REDEE FLU - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Small Molecules for RSV and Influenza A Infections - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 VIS-410 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 97 Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 98 Featured News & Press Releases 98 Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season 98 Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 98 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102

AbbVie Inc AIMM Therapeutics B.V. Aphios Corporation Celltrion, Inc. FluGen, Inc. Glide Pharmaceutical Technologies Limited ILiAD Biotechnologies, LLC Inovio Pharmaceuticals, Inc. Johnson & Johnson Medicago Inc. MedImmune, LLC Mucosis B.V. NanoViricides, Inc. OPKO Health, Inc. Sarepta Therapeutics, Inc. Takeda Pharmaceutical Company Limited VBI Vaccines Inc. Visterra, Inc. Zydus Cadila Healthcare Limited